These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 19288272

  • 1. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.
    Thomas NB, Hutcheson IR, Campbell L, Gee J, Taylor KM, Nicholson RI, Gumbleton M.
    Breast Cancer Res Treat; 2010 Feb; 119(3):575-91. PubMed ID: 19288272
    [Abstract] [Full Text] [Related]

  • 2. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
    Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI.
    Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
    [Abstract] [Full Text] [Related]

  • 3. (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.
    Farabegoli F, Papi A, Orlandi M.
    Biosci Rep; 2011 Apr; 31(2):99-108. PubMed ID: 20446926
    [Abstract] [Full Text] [Related]

  • 4. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
    Frankel LB, Lykkesfeldt AE, Hansen JB, Stenvang J.
    Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041
    [Abstract] [Full Text] [Related]

  • 5. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
    Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE, Nicholson RI.
    Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500
    [Abstract] [Full Text] [Related]

  • 6. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells.
    Fan P, Wang J, Santen RJ, Yue W.
    Cancer Res; 2007 Feb 01; 67(3):1352-60. PubMed ID: 17283173
    [Abstract] [Full Text] [Related]

  • 7. Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway.
    Dorssers LC, van Agthoven T, Brinkman A, Veldscholte J, Smid M, Dechering KJ.
    Breast Cancer Res; 2005 Feb 01; 7(1):R82-92. PubMed ID: 15642172
    [Abstract] [Full Text] [Related]

  • 8. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J, Liu M, Yang L, Tu G, Zhu Q, Chen M, Cheng H, Luo H, Fu W, Li Z, Yang G.
    Breast Cancer Res; 2015 May 21; 17(1):69. PubMed ID: 25990368
    [Abstract] [Full Text] [Related]

  • 9. AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells.
    Zhao W, Zhang Q, Kang X, Jin S, Lou C.
    Biochem Biophys Res Commun; 2009 Mar 13; 380(3):699-704. PubMed ID: 19285025
    [Abstract] [Full Text] [Related]

  • 10. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
    Chen B, Gajdos C, Dardes R, Kidwai N, Johnston SR, Dowsett M, Jordan VC.
    Int J Oncol; 2005 Aug 13; 27(2):327-35. PubMed ID: 16010412
    [Abstract] [Full Text] [Related]

  • 11. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
    Jordan NJ, Gee JM, Barrow D, Wakeling AE, Nicholson RI.
    Breast Cancer Res Treat; 2004 Sep 13; 87(2):167-80. PubMed ID: 15377841
    [Abstract] [Full Text] [Related]

  • 12. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
    Aesoy R, Sanchez BC, Norum JH, Lewensohn R, Viktorsson K, Linderholm B.
    Mol Cancer Res; 2008 Oct 13; 6(10):1630-8. PubMed ID: 18922978
    [Abstract] [Full Text] [Related]

  • 13. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
    Osipo C, Gajdos C, Cheng D, Jordan VC.
    J Steroid Biochem Mol Biol; 2005 Feb 13; 93(2-5):249-56. PubMed ID: 15860267
    [Abstract] [Full Text] [Related]

  • 14. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
    Hoffmann J, Sommer A.
    J Steroid Biochem Mol Biol; 2005 Feb 13; 93(2-5):191-200. PubMed ID: 15860262
    [Abstract] [Full Text] [Related]

  • 15. Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells.
    Moriai R, Tsuji N, Moriai M, Kobayashi D, Watanabe N.
    Breast Cancer Res Treat; 2009 Sep 13; 117(2):261-71. PubMed ID: 18815881
    [Abstract] [Full Text] [Related]

  • 16. Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer.
    Chong K, Subramanian A, Sharma A, Mokbel K.
    Anticancer Res; 2011 Jan 13; 31(1):23-32. PubMed ID: 21273576
    [Abstract] [Full Text] [Related]

  • 17. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
    Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D.
    Cancer Res; 2006 Apr 01; 66(7):3903-11. PubMed ID: 16585219
    [Abstract] [Full Text] [Related]

  • 18. Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells.
    Santen RJ, Fan P, Zhang Z, Bao Y, Song RX, Yue W.
    Steroids; 2009 Jul 01; 74(7):586-94. PubMed ID: 19138696
    [Abstract] [Full Text] [Related]

  • 19. Activation of mitogenic pathways and sensitization to estrogen-induced apoptosis: two independent characteristics of tamoxifen-resistant breast cancer cells?
    Scherbakov AM, Lobanova YS, Shatskaya VA, Onopchenko OV, Gershtein ES, Krasil'nikov MA.
    Breast Cancer Res Treat; 2006 Nov 01; 100(1):1-11. PubMed ID: 16990991
    [Abstract] [Full Text] [Related]

  • 20. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
    Berstein LM, Yue W, Wang JP, Santen RJ.
    Breast Cancer Res Treat; 2011 Jul 01; 128(1):109-17. PubMed ID: 20683653
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.